A practical reference on Freeze-thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-04. Anything still debated is marked as such rather than presented as settled.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Constant hunger Unexplained weight loss Weight gain Flu-like symptoms, including weakness and fatigue Blurred vision Slow healing of cuts or bruises Tingling or loss of feeling in hands or feet Recurring gum or skin infections Recurring vaginal or bladder infections Acetone odor during diabetic ketoacidosis (DKA)
They also included giving the Reserve Forces and Cadets Associations the power to produce an annual report to Parliament on the state of the volunteer reserves (the Royal Naval Reserve, The Royal Marines Reserve, the Army Reserve and the Royal Auxiliary Air Force). In January 2021, the Army Reserve trained strength stood at 26,820. (This figure excludes recruits undergoing phase 1 training and various non-deployable categories such as University Officers' Training Corps). During 2020, three reserve infantry battalions, 7 Rifles and 5 Fusiliers followed by 6 Rifles, provided the framework battalion for peacekeeping in Cyprus and over the winter 20/21 the Royal Yeomanry provided a composite squadron for a six-month tour on armoured reconnaissance as part of Britain's forward presence in Estonia. Army Reservists have a minimum commitment to serve 27 training days per year or 19 days for some national units. This period normally includes a two-week period of continuous training either as an Army Reserve unit, on courses or attached to a Regular unit. Army Reserve soldiers are paid at a similar rate to their regular equivalents while engaged on military activities.
== External links == Works by or about Frederick Gowland Hopkins at the Internet Archive Frederick Gowland Hopkins on Nobelprize.org Frederick Gowland Hopkins at Find a Grave Biography by N.J.T. Thomas Chemical genealogy Frederick Gowland Hopkins[link removed]
Sources: en.wikipedia.org
Other risk factors for overdose mortality related to opioids at the individual level include clinical factors such as cardiovascular disease, comorbid mental disorders and psychological stress (e.g., depression), a history of substance use disorders, economic and community distress (e.g., low education, high unemployment), and characteristics such as male sex and middle age.
Flip–flop kinetics, or flip–flop pharmacokinetics, describes an atypical situation in pharmacokinetics where a drug's rate of absorption or the rate at which it enters the bloodstream is slower than its elimination rate. That is, when the ka (absorption constant) is slower than ke (elimination constant). These circumstances can occur with sustained-release formulations, depot injections, and some subcutaneous or intradermal injections. In the resulting slope of log plasma concentration (log Cp) versus time, the apparent ke is determined by the ka, and the apparent ke is smaller than when the drug is administered intravenously or by immediate-release formulation. Depot injections such as depot antipsychotics and long-acting injectable steroid hormone medications like estradiol valerate, testosterone enanthate, and medroxyprogesterone acetate are examples of drugs with flip–flop kinetics. The term "flip–flop" indicates that the downward slope more closely represents ka rather than ke. Flip–flop kinetics can create difficulties in the determination and interpretation of pharmacokinetic parameters if not recognized.
24 January The discovery of 85 exoplanet candidates based on data from the TESS observatory is reported. All have orbital periods of between 20 and 700 days, with temperatures similar to those of Solar System planets. A global analysis of groundwater levels reports rapid declines of over 0.5 meters per year are widespread and that declines have accelerated over the past four decades in 30% of the world's regional aquifers. The study also shows cases in which depletion trends have reversed following interventions such as policy changes. 25 January – The Laser Interferometer Space Antenna (LISA) is given the go-ahead by the European Space Agency (ESA). It will launch in 2035. 26 January – Astronomers report the detection of water vapor in the atmosphere of GJ 9827 d, an exoplanet about twice the size of Earth. 29 January Elon Musk's startup Neuralink implants their first microchip into a human brain. A robotic sensor able to read braille with 87.5% accuracy and at twice the speed of a human is demonstrated. 31 January – NASA reports the discovery of a super-Earth called TOI-715 b, located in the habitable zone of a red dwarf star about 137 light-years away. Promising innovations relating to global challenges are reported: a self-powered solar panel cleaning system using an electrodynamic screen, removing contaminants through high-voltage electric fields, is demonstrated (4 Jan), an atmospheric water generator (WaterCube) for humidity levels above 40% is released (9 Jan).
=== Diagnosis === It is difficult to differentiate the effects of low level metal poisoning from the environment with other kinds of environmental harms, including nonmetal pollution. Generally, increased exposure to heavy metals in the environment increases the risks for several diseases.
Sources: en.wikipedia.org
== History == Bacitracin was isolated by Balbina Johnson, a bacteriologist at the Columbia University College of Physicians and Surgeons. Its name derives from the fact that a compound produced by a microbe in young Margaret Treacy's (1936–1994) leg injury showed antibacterial activity.
==== A-ring reductases (5alpha- and 5beta-reductases) ==== Cortisol is also metabolized irreversibly into 5-alpha tetrahydrocortisol (5-alpha THF) and 5-beta tetrahydrocortisol (5-beta THF), reactions for which 5-alpha reductase and 5-beta-reductase are the rate-limiting factors, respectively. 5-Beta reductase is also the rate-limiting factor in the conversion of cortisone to tetrahydrocortisone.
=== Senior team === Townsend's first call-up to the senior England squad came in September 2013, for the World Cup qualifiers against Moldova and Ukraine. He made his senior debut against Montenegro in a World Cup qualifier on 11 October, during which he scored the third goal of a 4–1 win with a "low swerving finish" from outside the penalty area after 78 minutes, two minutes before being substituted, and was named man of the match. He earned a second cap four days later against Poland, playing almost all of the 2–0 home win. A second England goal came in the Euro 2016 qualification campaign in a 5–0 win over San Marino on 9 October 2014, as he came on for the final third of the match. His next appearance marked his third England goal; on 31 March 2015 he scored the equaliser in the 79th minute against Italy, having come on seven minutes earlier in a friendly match which ended 1–1. The 20-yard strike was described as a "sweet right-foot drive into the bottom corner"; Townsend took to Twitter immediately after the match to respond to Paul Merson after he had said Townsend's club form did not justify him being in the England team.
==== Antistaphylococcal antibiotics ==== Cloxacillin (by mouth or by injection) Dicloxacillin (by mouth or by injection) Flucloxacillin (by mouth or by injection) Methicillin (injection only) Nafcillin (injection only) Oxacillin (by mouth or by injection) Antistaphylococcal antibiotics are so-called because they are resistant to being broken down by staphylococcal penicillinase. They are also, therefore, referred to as being penicillinase-resistant.
=== Initial descriptions and discovery === One of the earliest recorded outbreaks of foodborne botulism occurred in 1793 in the village of Wildbad in what is now Baden-Württemberg, Germany. Thirteen people became sick and six died after eating pork stomach filled with blood sausage, a local delicacy. Additional cases of fatal food poisoning in Württemberg led the authorities to issue a public warning against consuming smoked blood sausages in 1802 and to collect case reports of "sausage poisoning". Between 1817 and 1822, the German physician Justinus Kerner published the first complete description of the symptoms of botulism, based on extensive clinical observations and animal experiments. He concluded that the toxin develops in bad sausages under anaerobic conditions, is a biological substance, acts on the nervous system, and is lethal even in small amounts. Kerner hypothesized that this "sausage toxin" could be used to treat a variety of diseases caused by an overactive nervous system, making him the first to suggest that it could be used therapeutically. In 1870, the German physician John Müller coined the term botulism to describe the disease caused by sausage poisoning, from the Latin word botulus, meaning 'sausage'. In 1895, Émile van Ermengem, a Belgian microbiologist, discovered what is now known as Clostridium botulinum and confirmed that a toxin produced by the bacteria causes botulism.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.